Granahan Investment Management LLC Purchases 144,189 Shares of Stoke Therapeutics, Inc. $STOK

Granahan Investment Management LLC lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 75.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 335,586 shares of the company’s stock after buying an additional 144,189 shares during the quarter. Granahan Investment Management LLC’s holdings in Stoke Therapeutics were worth $10,927,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Kestra Advisory Services LLC bought a new position in Stoke Therapeutics during the fourth quarter worth about $26,000. KBC Group NV bought a new stake in Stoke Therapeutics in the 1st quarter valued at about $36,000. Harbour Investments Inc. boosted its holdings in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the period. Generali Investments Management Co LLC boosted its holdings in Stoke Therapeutics by 41.0% in the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after purchasing an additional 718 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after purchasing an additional 658 shares in the last quarter.

Stoke Therapeutics Stock Down 1.2%

STOK stock opened at $29.30 on Friday. The company has a market cap of $1.82 billion, a PE ratio of -10.43 and a beta of 1.17. The business has a 50-day simple moving average of $30.41 and a 200 day simple moving average of $32.15. Stoke Therapeutics, Inc. has a 52 week low of $12.25 and a 52 week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.01. The business had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. On average, analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the completion of the transaction, the general counsel directly owned 18,086 shares in the company, valued at approximately $541,675.70. The trade was a 7.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the sale, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

STOK has been the topic of several recent research reports. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. The Goldman Sachs Group began coverage on Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 price target for the company. Finally, BTIG Research reissued a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.00.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.